Family planning method discontinuation among Nigerian women: Evidence from the Nigeria Demographic and Health Survey 2018

Agbana, Richard Dele; Michael, Turnwait O.; Ojo, Tolulope

doi:10.1016/j.jtumed.2022.08.003

Cited by 1 publication

(2 citation statements)

References 34 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 19% of married women aged 15–49 in Nigeria utilize modern contraception, even though 98% of sexually active unmarried women and 94% of married women are aware of their options [ 1 , 2 ]. In Nigeria, the public sector provides more modern contraceptive methods than the private sector (54% vs. 41%).…”

Section: Introductionmentioning

confidence: 99%

“…This has been true in Nigeria and other African countries, where for example, the community-based distribution policy was critical for the uptake of injectable contraceptives because it removed the access barrier for many people who could not go to health facilities for one reason or another [ 14 ]. Researchers have alluded to the need for policy frameworks to boost family planning use, identify common adverse reactions, and focus on educating the public about the negative implications of poor family planning uptake on people, families, and the country [ 1 , 4 ]. Also, studies have shown that the lack of clear policy and implementation guidelines limited innovation within Nigeria's health system, including the introduction of new contraceptive technologies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Scale-up of the DMPA-SC in Nigeria: Why policy matters

Akinyemi

Danfakha

Adefalu³

et al. 2022

BMC Women's Health

View full text Add to dashboard Cite

Background Injectable contraceptives have contributed substantially to Nigeria's rise in modern family planning methods usage. They are one of the most commonly used and preferred means of contraception among women in the country. Enabling policies are required to assure contraceptive access, security, and use. This study aimed to investigate the policy environment and how it supports or limits Nigeria's introduction and scale-up of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC). Methods The design of this mixed-methods study was cross-sectional. Desk reviews of policy papers, key informant interviews, and in-depth interviews were used to obtain information from respondents about the introduction of DMPA-SC in Nigeria and how existing policies influenced its scale-up. Data on DMPA-SC and other injectables were gathered from Nigeria's national electronic logistics management information system. Results The findings suggest that policies such as task-shifting and task-sharing, cost-free policies, reproductive health policies, and others created an enabling environment for the scale-up of DMPA-SC adoption in Nigeria. The inclusion of DMPA-SC on the essential medicines list and the approved patent medicines list facilitated the scale-up process by ensuring private sector participation, removing economic barriers to access, fostering greater collaboration among health worker cadres, improving intersectoral partnerships, and improving logistics and client access. Despite significant anomalies in some implementing policies, injectable contraceptive consumption data demonstrate a progressive increase in DMPA-SC use during the study period. The results also indicate that policy initiatives have a favorable impact on the use of DMPA-SC throughout the country. Conclusion The existence of policies, the active participation of stakeholders, and the political will of the Nigerian health system's leadership have all aided in the scaling-up of the DMPA-SC. Understanding how to build an enabling policy climate is critical for providing women with family planning options. These lessons from Nigeria emphasize the importance of these levers, which should be considered by teams intending to introduce innovative health products, particularly in developing countries.

show abstract

Section: Introductionmentioning

confidence: 99%